A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors (NCT04707248)
Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates, PC HOPE (A)A HOPE) — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Arizona Oncology Associates, PC HOPE (A)A HOPE) — Tucson, Arizona
- Rocky Mountain Cancer Center — Denver, Colorado
- Florida Cancer Lake Mary — Lake Mary, Florida
- Oklahoma University — Oklahoma City, Oklahoma
- SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- National Cancer Center Hospital — Chuo Ku, Tokyo
- National Cancer Center Hospital East — Kashiwa-shi, Tokyo
- National Hospital Organization Kyusyu Cancer Center — Fukuoka,
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research — Kōtoku,
- National Hospital Organization Shikoku Cancer Center — Matsuyama,
- Shizuoka Cancer Center — Nakatogari,
- Saitama Medical University International Medical Center — Saitama,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.